to fever, the patient had significant weight loss. He had no other history of cough, expectoration, loose stools, dysuria, or increased urinary frequency. He had no history of tuberculosis in the past and no contact history.
On examination, he was febrile and pallor. There was no lymphadenopathy, his chest examination was unremarkable, and his abdominal examination did not reveal any tenderness over the allograft.
Laboratory investigations revealed anemia (Hemoglobin (Hb)-5.6 g/dl), leukocytosis (Total Leukocyte Count (TLC) -15,100 cells/cubic.mm), graft dysfunction (serum creatinine: 1.62 mg/dl), mild jaundice (serum bilirubin: 1.6 mg/dl), thrombocytopenia with platelet count 0.57 lakh/cubic.mm, erythrocyte sedimentation rate 110 mm/1 h. Other laboratory investigations like serum electrolytes, liver function tests, urine and stool analysis, MP QBC, blood and urine cultures were unrevealing. HBsAg and anti-HCV antibody were negative, and HIV serology was nonreactive.
Chest X-ray was normal, and ultrasonography of abdomen showed mild renal parenchymal disease changes in transplant kidney. Noncontrast CT done was negative (contrast-enhanced CT [CECT] avoided in this case due to contrast-induced nephropathy). In spite of an extensive evaluation, we were unable to detect the cause of fever, which was unremitting for 3 weeks -a classical PUO. Later, F18 FDG PET/CT was done to localize the fever focus.
F18 FDG PET/CT showed the focal area of moderately increased FDG uptake in the left lobe of prostate with no corresponding morphological abnormality on CT with maximum standardized uptake value uptake of 6 [ Figure 1 ].
Considering the diagnosis as prostatic infection patient has been put on broad-spectrum antibiotics (ciprofloxacin 400 mg intravenous (IV) bid and also received metronidazole 500 mg IV qid) within a week, there has been subsidence of fever and the serum creatinine levels returned to normal (serum creatinine-1.1 mg/dl), indicating the cause of raise in serum creatinine levels to be due to infection.
disCussion
F18 FDG PET/CT detects the metabolic changes far ahead of the morphological changes which are delineable by other modalities, thus aiding early detection of the lesions which may not be apparent on CT. Hypermetabolism in normal-sized diseased lymph nodes can be demonstrated only on PET/CT. [6] Early identification of metabolic changes by PET before the morphological changes manifested on CECT could explain the relatively low sensitivity of the CECT as compared to F18 FDG PET/CT. Although CECT is the conventional imaging modality of choice, further it is not indicated in postrenal transplant setting due to the risk of contrast-induced nephropathy.
F18 FDG PET/CT has gained importance for the detection of infection in renal transplant patients as activated inflammatory leukocytes show increased FDG uptake in which makes FDG PET a very sensitive imaging modality for diagnosis of infection.
Originally, F18 FDG PET/CT was well-accepted clinical tool for routine assessment of cancer. FDG is a marker of increased intracellular glucose metabolism. Nonspecific 18F FDG accumulation can be observed at the sites of inflammation during PET imaging of patients and evolved into a promising imaging tool for diagnosis of inflammatory and infectious causes. The nonspecificity of 18F FDG is an asset in evaluating patients with FUO because the tracer accumulates in infections, malignancies, and inflammatory diseases -the three principal causes of FUO.
F18 FDG PET/CT has about 90% sensitivity in diagnosing abdominopelvic abscesses, active tuberculosis, atypical pneumonias, renal abscess, focal nephritis, bacterial colitis, diverticulitis, and infected vascular grafts. [7] Recipients of SOTs have a 6%-10% incidence of opportunistic infections in the Indian subcontinent as against 1.4%-9.4% in the Western countries. The mortality rate in the Indian subcontinent is also very high, ranging from 70% to 100%. [8] This is because of intense immunosuppression, delay in diagnosis and treatment, and overcrowded environment. About 87% of the febrile episodes occurring in the transplant patients hospitalized in the Intensive Care Unit were due to infections. [9] F18 FDG PET/CT has been shown to be clinically useful in up to 70% of these cases with a high negative predictive value of up to 100%. [10] In the present case of renal transplant recipient, the patient had fever for >3-week duration, and he was evaluated using all the conventional imaging modalities which did not reveal any significant clue in diagnosis.
Finally, he was referred for F18 FDG PET/CT where an infective focus was localized in the left lobe of prostate which is supposed to be an unusual site.
Prostatic abscess is a rare clinical entity in this antibiotic era where diagnosis is difficult from clinical presentation as it mimics several other diseases of lower urinary tract such as dysuria, urgency, and frequency. Prostatic abscess mainly affects diabetic and immunosuppressed patients. [10] Two different etiologic patterns have emerged with effective antibiotic therapy. The first is primary abscess in elderly patients with underlying lower genitourinary tract diseases, predominantly Gram-negative bacterial infection. The second pattern is metastatic abscess to the prostate from a septic focus elsewhere. This group is characterized by Gram-positive bacterial infections, often Staphylococcus aureus.
The signs and symptoms of prostatic abscess are highly variable. The classical findings include dysuria, frequency, and urgency (96%); fever (72%); acute urinary retention (36%); and perineal pain (32%). In our case, the patient did not have any of these symptoms except for fever. Complications of prostatic abscess include spontaneous rupture into the urethra, perineum, bladder or rectum, chronic prostatitis, infertility, and sepsis either due to a late diagnosis or inadequate drainage of the abscess.
Prostatic abscess is an uncommon but relatively serious disease that has the potential for causing problems if not diagnosed at the early stage and treated promptly. Careful clinical examination and imaging modalities may assist in diagnosis. Adequate drainage and effective antimicrobial treatment are the ideal therapy for this disease.
In our case, F18 FDG PET/CT could localize the focus in prostate and aid in the diagnosis. Thus, F18 FDG PET/CT emerges as a valuable technique to manage complications in posttransplant recipient patient, and it can also be considered in patients with FUO and severe unexplained inflammatory syndrome scenarios and where conventional imaging is inconclusive.
The advantage of F18 FDG PET/CT is that it allows for one time whole-body evaluation and multiple foci of infection can be identified on a single scan. Furthermore, functional data with F18 FDG PET/CT are complimentary to anatomical data provided with CT. The other advantage of using F18 FDG PET/CT in patients of renal transplant is the avoidance of CECT preventing contrast-induced nephropathy. F18 FDG PET/CT scan has several advantages over conventional imaging techniques including high spatial resolution and the ability to secure results within a short period of time. [11] The experience with F18 FDG PET/CT scan should eliminate application of many unnecessary invasive and noninvasive diagnostic techniques for the detection of main disease underlying FUO etiology. Moreover, the availability and cost of PET/CT have suited for making it a modality of choice at our institute with a cost of around 13,000.
ConClusion
F18 FDG PET/CT is better than conventional imaging modalities in making a specific diagnosis in the evaluation of PUO. It also helps in deciding the best possible site for biopsy. From our study, we can infer that F18 FDG PET/CT may be used as an initial noninvasive diagnostic tool for the assessment of patients with PUO, especially in posttransplant recipients. Further, F18 FDG PET/CT study could be cost-effective noninvasive diagnostic modality in the FUO, if used at an early stage, helping to establish an early diagnosis, reducing hospitalization days due to diagnostic purposes, and the repetition of unnecessary tests.
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